<SEC-DOCUMENT>0001193125-12-110910.txt : 20120313
<SEC-HEADER>0001193125-12-110910.hdr.sgml : 20120313
<ACCEPTANCE-DATETIME>20120313070659
ACCESSION NUMBER:		0001193125-12-110910
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120313
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120313
DATE AS OF CHANGE:		20120313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911663741
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34475
		FILM NUMBER:		12685729

	BUSINESS ADDRESS:	
		STREET 1:		1420 5TH AVE
		STREET 2:		SUITE 2600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		206-676-5000

	MAIL ADDRESS:	
		STREET 1:		1420 5TH AVE
		STREET 2:		SUITE 2600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d314471d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES SECURITIES AND
EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, DC 20549 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT
REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): March&nbsp;13, 2012 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>OMEROS CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Washington</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-34475</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>91-1663741</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of<BR>incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer<BR>Identification No.)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1420 Fifth Avenue, Suite&nbsp;2600 Seattle, Washington 98101 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(206) 676-5000 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On&nbsp;March 13, 2012, we issued a press release announcing the results of our Phase 3 clinical trial evaluating OMS302 in patients
undergoing intraocular lens replacement surgery. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Exhibits </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated March&nbsp;13, 2012</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-2-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OMEROS CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Gregory A. Demopulos, M.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory A. Demopulos, M.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer and<BR>Chairman of the Board of Directors</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: March&nbsp;13, 2012 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated March&nbsp;13, 2012</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d314471dex991.htm
<DESCRIPTION>PRESS RELEASE DATED MARCH 13, 2012
<TEXT>
<HTML><HEAD>
<TITLE>Press Release Dated March 13, 2012</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g314471g63x70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Omeros&#146; Ophthalmology Product OMS302 Achieves Primary and Secondary </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Endpoints in Phase 3 Clinical Trial </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>-- Company to Host Conference Call Today at 9:00 a.m. EDT -- </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Seattle, WA &#150;
March&nbsp;13, 2012</B> &#150; Omeros Corporation (NASDAQ: OMER) today reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302 met its primary endpoint by
demonstrating statistically significant (p&lt;0.00001) maintenance of intraoperative mydriasis (pupil dilation). OMS302 also demonstrated statistical superiority (p&lt;0.00001) over placebo in reduction of pain in the early postoperative period. The
data for both endpoints are clinically meaningful. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros&#146; proprietary PharmacoSurgery&#153; product designed to maintain intraoperative mydriasis and
reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This multicenter, double-blind, Phase 3
clinical trial enrolled 405 patients randomized 1:1 to receive either OMS302 or placebo. The primary endpoint was maintenance of intraoperative mydriasis (pupil dilation), which is critical to the safety and surgical ease of lens replacement
surgery. Pupil constriction during surgery increases the risk of injury to intraocular structures and can substantially prolong surgical time. In addition to statistical superiority over placebo in maintenance of mydriasis and the secondary endpoint
of reduced postoperative pain, OMS302 achieved p values of less than 0.05 in a series of other clinically relevant measures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this study,
OMS302 was well-tolerated. The most common adverse events were those related to surgery, specifically eye pain, eye inflammation, headache and increased intraocular pressure. The incidence of these adverse events was similar between OMS302- and
placebo-treated patients. The complete data are expected to be presented at an upcoming major ophthalmology meeting. Omeros also plans to publish the data in a leading peer-reviewed ophthalmology journal. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The data from this study are compelling and demonstrate that OMS302 addresses a universal need in lens replacement surgery,&#148; stated Alan S.
Crandall, M.D., director of glaucoma and cataract, senior vice chairman of ophthalmology and visual sciences at the Moran Eye Center, University of Utah, and past president of the American Society of Cataract and Refractive Surgery.
&#147;Ophthalmologic surgeons are committed to successful outcomes for their patients, and maintenance of mydriasis and pain management are central to that success. Given the drug&#146;s demonstrated effects on these two challenges facing all lens
replacement surgeons, I expect that OMS302 could become widely used.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Maintenance of mydriasis throughout the procedure is
essential for the safety of lens replacement surgery,&#148; stated Mark I. Rosenblatt, M.D., Ph.D., associate professor of ophthalmology, Weill Cornell Medical College. &#147;A constricted pupil decreases the surgeon&#146;s operative field, which
can make the procedure more difficult to perform and potentially increases the rates of complications, including rents in </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the lens capsule or the retention of cortical lens material with more frequent posterior capsular opacification or lens dislocation. In addition, the pain relief from this drug combination
improves the surgical experience for the patient and assists the surgeon in pain management during the critical early postoperative period.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;This is an important day for Omeros. This achievement marks our transition to a company preparing, rather than hoping, to commercialize our first product,&#148; said Gregory A. Demopulos, M.D.,
chairman and chief executive officer of Omeros. &#147;Following our recent successful meetings with U.S. and European regulators, we plan to begin enrolling patients in our second Phase 3 trial early next month and to submit marketing applications
in both the U.S. and Europe in the first part of 2013.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Omeros&#146; OMS302 Program </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">OMS302 is Omeros&#146; product being developed for use during intraocular lens replacement (ILR) surgery, including cataract surgery and refractive lens
exchange. OMS302 is a proprietary combination of ketorolac, an anti-inflammatory agent, and phenylephrine, a mydriatic (pupil dilating) agent. FDA-approved drugs containing each of these agents have been used in ophthalmological clinical practice
for more than 15&nbsp;years, and both are contained in generic, FDA-approved drugs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ILR surgery involves replacement of the original lens of
the eye with an artificial intraocular lens. These procedures are typically performed to replace a lens opacified by a cataract or to correct a refractive error of the lens (i.e., refractive lens exchange). OMS302 is added to standard irrigation
solution used in ILR surgery and delivered intracamerally to maintain intraoperative mydriasis (pupil dilation), to prevent surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. Maintenance of mydriasis is
critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Ophthalmological Procedures (Cataract and Other Lens Replacement Surgery) </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are 3.6&nbsp;million intraocular lens replacement procedures expected in the U.S. this year and 20&nbsp;million worldwide, with a projected annual growth rate of three to four percent, resulting in
over four million U.S. and 23&nbsp;million worldwide procedures by 2016. An important segment of this market is premium lens procedures. The premium market includes toric, multifocal and accommodating lenses. In 2011, in the U.S., 16 percent of all
lens replacement procedures were premium and that number is expected to grow to 26 percent in 2016. Refractive lens exchange is also a growing segment of the lens replacement market. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Conference Call and Webcast Today at 9:00 a.m. EDT </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Omeros management will host a
conference call today, March&nbsp;13, at 9:00 a.m. EDT to discuss today&#146;s news.&nbsp;To access the live call by telephone, please dial 866-788-0541 (United States and Canada) or 857-350-1679 (International). The passcode is 98382880.&nbsp;In
addition, the live conference call will be webcast and can be accessed on the &#147;Events&#148; page of the Company&#146;s website at <U>http://www.omeros.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A replay of the webcast will be available on the Company&#146;s website for one week.&nbsp;A telephone replay will also be available for one week starting at 9:30 a.m. EDT today, which can be accessed by
dialing 888-286-8010 (United States and Canada) or 617-801-6888 (International) and entering passcode 35583097. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Omeros Corporation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system.
The Company&#146;s most clinically advanced product candidates are derived from its proprietary PharmacoSurgery&#153; platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has
four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR
platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements as
defined within the Private Securities Litigation Reform Act of 1995, which are subject to the &#147;safe harbor&#148; created by those sections. These statements include, but are not limited to, statements regarding the potential benefits of OMS302;
the Company&#146;s plans to present and publish the data from the Phase 3 clinical trial; OMS302&#146;s expected adoption by surgeons; Omeros&#146; plans to begin enrolling patients in its second OMS302 Phase 3 trial early next month and to submit
marketing applications in both the U.S. and Europe in the first part of 2013; the projected number of ophthalmological procedures in the U.S. and worldwide; and that Omeros may have capability, through its GPCR program, to add a large number of new
drug targets and their corresponding compounds to the market. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of this press release. Omeros&#146; actual
results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in the
Company&#146;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November&nbsp;8, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and
the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jennifer Cook Williams
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cook Williams Communications, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor and Media Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">360.668.3701
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">jennifer@cwcomm.org </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g314471g63x70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g314471g63x70.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`(,`N@,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`Y34O$XM/&UAIB;FCQY4P&?O28V\<
M#C"\\\,>]>76QG)BXTEML_5[?=^K/7H8'GP4ZSWW7HKW^_73ND=77J'D!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`%/5M1CTG2KB^E&5
MA3(7^\>@'?&20,^]8UZJHTW4?0WP]%UZL:<>IXDBSZKJ9W.IFN)"SR-PHR<L
MQQT`Y)]`#7Q:4JU37=_TV?=-QH4]%HE_PR]>B/9?#^L0ZWI2W,)<[',;>9C=
MD="<`#)&#QP,XK[#"XB.(I\T?3^OST/B<9AI8:KR2]?ZZ[Z:FI74<@4`%`!0
M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'`?$O4`([+35*DDF=Q@Y
M'55YZ<Y;\A7@YQ5TC27K^B_4^BR2CK*J_3]7^ASD&C75IX2GUM-C+/B($-\T
M:%BK'ZDA5X)X9L]:\Z.'G##.NNNGHKV?Z+T;/3EB83Q2P[Z:^KM=?J_5(M>`
MM8BTS69(;F98K>YCP68@*&7D$D].-P^I%:Y7B%1JN,G9/\U_3,<VPTJU%2@K
MM/\`!_TCLU\<Z-+J-O96S3SM.ZHKI'A02<8.[!_2O8694)5%"-W?R_S/$>58
MB-.52=E;S[>ESI:](\L*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`CN)X[6VEN)FVQ1(7=L9P`,DU,I*$7*6R*A!SDHQW9XG?W$^OZRUR-K7%Y-L
M2'/*]`HS@#T&?8Y]_BZLI8FKS=9/;\O+^M3[JE".%H\G2*W_`#\_/\CT?Q1J
M%GX=\,G3TCR]S$\,2(H0<C#,<``?>S@#DG\OHL;5IX7#^S2W32_5]CYG`4:F
M+Q/M6_A:;Z^BUUZ'DM?*GV!TNFZ))86MGXCFDWV,,L<I\D9;&X@C#%>0RJ.X
M^;(SBO1HX9THQQ,G[J:>GKYVZV7S/,KXI592PD5:336OIY7Z-OY6ZGH.C>+=
M*UN;R+>1XKCG;%,N&8#N,$@_3.>#Q7OX?'4<0^6+L^S/F\3E]?#+FDKKNC=K
MN.`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@#F/'FHI9>&I8/,9)KH
MB-`K8)&06_#`P?J/6O,S.JJ>'<;ZO3_,]7*:+J8E2MI'7_+Y]?D9?@K18)+I
M-5*KOMHS!E"A5Y.A;Y&/0?+R/F&&ZGCFR[#Q<E5[:=-^^C[:>>_4Z\SQ,HQ=
M'^9WZ[=M5WU\M8]#FO%&JG7]?F56MXX;82)$^1\ZKDYW=]V.!TY'J2?-QM?Z
MS6>R2O;Y>?GT/4P%#ZK06[;M?ROY>77^D5=5\.W6D:587EPKJUSNWQLF/*(^
MZ"<]2.<<'@^E95\).A3C.77\/^'-</C(8BK.G#[/7OW^XTO#,CZIH>H^&HWB
MCFN"LT+2'`)!7<"?HH(`'8UTX-NM1GA5HWJOPO\`EV[G+CDJ%>&+=VEH[?.W
MY]^Q1U3PAK.E(\DMKYL"=983N7&,DXZ@#GD@"L*V`KT4VU==U_5SHH9CAZ[2
MC*S[/3_@?B=;X#\2R7F_2[Z9Y;@9DBED?)8=UYY)')[\9Z8KULLQCG^ZJ.[Z
M/]/Z_0\?-L"J=JU-66S2_/\`K]3N:]L\`*`"@`H`*`"@`H`*`"@`H`*`"@`H
M`*`"@`H`*`/,=<N;C5?'$BV$F)H,6D#(65@QSN)P0P"Y<E@"/E&1@\_-8F<J
MV,:IO5>ZOUZWTUU6FFNY]5A80H8).HM'[SVVZ=+:Z:/75VU1Z%I>FPZ38):0
M,[JO\<A!9NPR0!G```]@!VKWZ-&-&"A'^OZV]#YRO7E7FYR_#;^NOJ>5WFGP
M6NH+:W,%O(5F\F6Z2;RHV=PI(QR!LRPR``,KD=F^7J4HPGR22WLW>RN[?^DZ
M[+32ZZ/ZVG6E.GSP;6ETK7=E?_TK3=W>MGU7I7B;2CK&@7-I&JF;&^+(!^8<
M@#/3/(S[U]'C*'MZ,H+?IZ_UH?+X&O\`5Z\9O;KZ?\#<\?TG49-)U6VOHAEH
M7R5_O#H1WQD$C/O7R-"JZ-15%T/M,115>E*F^I[A&\%_9*ZA9;>XC!`9>&5A
MW!]0>AK[9.-2%UJG^1\$U*E.VS3_`!1YSIVGP:5\4TL[4,(8RQ4,<XS"3C/X
MU\]1I1HYBH0V7^1]-6K2KY8ZD]W_`/)6/3*^D/E@H`*`"@`H`*`"@`H`*`"@
M`H`*`"@`H`*`"@"CK.H#2M&N[TE08HR4W`D%NB@X]20*PQ%7V-*53M^?0Z,-
M1]O6C3[O\.OX&-X6\,6VFQQ:A*C->O&`"Z!/+7H/E`^5MN-W4YSSR<\>"P4*
M251_%]UOET=M]^NIVX_'3K-TH_"GZW^?57VVTMH=/7IGE'":]H-OIFK/JBPV
M\XF,DWE3*_)4*[C.&4Y59,`@8W9&<#'AXG"QHU7523O=V=_)ONM4GO;?RT^@
MPF+G6I*BVU:RNK=;I=GHVKVOMKOKVMI=P7UK'<VLJRPR#*LO?_/I7LTYQJ14
MX.Z9X52G*E)PFK-$U609^J:YIVC>5_:%QY/FYV?(S9QC/0'U%<];$TL/;VCM
M<Z:&%K8B_LE>WH<EHWB/04U6_P!:O;KRKRZ<HB>6YV1#`4'`(W':">3VQCFO
M*P^+PRJ2KSE:3]=%_GH>QB<%BG2AAZ<;QCYK5]?EKIL=!;^,=!NKF*WAO]TL
MKA$7RG&23@#I7?',,-.2C&6K\G_D>;/+<5"+E*.B\U_F;<;B2-74,`P!`92I
M_$'D?0UVIW5T<+7*[,=3$%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`&?J6EQZK-
M:I=1I):0N961NK..%SV*X+9'KCMFN>M159Q4U>*U^?3Y;_@=-"NZ"DX.TGI\
MNOSVM\_(T*Z#F,+Q'KMUH$*7*:9]JM3P\@FVE#VR-IX/KZ\>F>'%XF>&7,H7
M7KM^!WX+"0Q3<'/EEVMO^)R\_P`1X;J%H;C0DEB;JCSAE/?H4KS)9O&:Y94[
MKU_X!ZT,EE!\T:MGZ?\`!*ECX]&FCR[;2E$!()5IR6X7:!G'8!`..BG.2<C*
MGFGLM(0T]?*W;M;[NK=S:KE/MM9SU]/._?O=[]=+)6.W\-:]_P`)#ITEW]F^
MS[)3'MW[LX`.<X'K7M8/%?6J;G:VMCP<;A/JE10O?2_8P?B'IUW?K8&UMY9C
M$)"1'&S]2@`X!QW/..AKAS:C.IR<BO:_1^1Z.3UJ=+GYVE>V[2[]SCHO"6N2
MM(BZ?*'201[6&W/#'(8_*0-O7/<>M>/'`8AW7+Y?G\NGY'M2S##1L^=6M?\`
M+IO?7MW/0?#WA.#3K"V:X65+K#-(JS=&9=O50.@W8ZXWM@GK7OX3`QI03EOZ
M]6K=+;=.UWZGSF,S"56I)1MR]-.B=^M]]+][+3H=/7IGE!0`4`%`!0`4`%`!
M0`4`%`!0`4`%`!0`4`%`!0`V2-)8VCD17C<%65AD$'J"*32:LQIN+NMSA->^
M'K75^;C2)(((Y,EXI"0JG_9P#P?3MV]!X>*RISGS46DGT_R/H,)G"A#EKIMK
MJOU,K_A6VL?\_-E_WV__`,37+_8]?NOQ_P`CK_MK#]G^'^9V?A'1+G0-*EM;
MIXG=YC(#$21@JH[@>E>Q@,-/#4W"?>^GR/#S'%0Q553@G:UM?F;]=YYX4`%`
M!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0!XUK'Q1UOQ'KD6B>!X?+<R-LG?9NN`JD\*XP@X8\\
MG`Z<BO3AA84X\]8\Z>)G.7+2#Q%J/Q2\'VT.IWVJVM]9K(!)Y,",J\C`?Y%(
M#=,C\P2,E..&JOEBK/\`KS"I+$4ES-W1Z+X1\7:?XPT@7EF?+F3"W%NQRT+?
MU!YP>_L00.*M1E1E9G92JQJQNB'X@ZM>Z'X'U'4=.G\B[A\O8^T-C,BJ>"".
MA-/#PC.JHRV%7DX4W*.YQGPN^)%[KFIRZ-KUSY]W-\]I((0N<`ED.W`Z#(X_
MO<]!75BL-&$>>"TZG-AL0YOEGN>LUYQWG@?B_P"+&NCQ/>0Z!J*0:;`WE1E8
M8W\PCJ^XAL@G.,<8QQG->O1PD.1.:U/+JXJ?.U!Z'OE>0>H>>>//BA%X1U`:
M79V27EZ8=[LTH"0L?N@@9)/<CY>".>>.W#X5U5S-V1R5\3[)\J5V9FG6'Q=O
M]/@NVUVRM#*N[R;B%%D0=MP$1P>^,Y'?!XJY2PD7;EO_`%ZD1CB6KWM_7H=G
MX+O/$5UH\J^)[1+?4+>;ROE4`2+L0A\@E222<[>,C&!BN:NJ:E^[>AT47-Q_
M>+4\P^(/Q!\4:'XXU'3M.U3R+2'R]D?D1MC,:D\E2>I-=V'P]*=)2DM3BKUZ
MD*CC%Z%GQ!KOQ-\#O!?:K?V5]9,VS*QIY;.0V%("H^0%SQQTY[4J=/#5M(JS
M_KU14YXBCK)W1Z!X#\8Q>,M"-T8TAO8&\NYA5@0&QD,!G(4\XSW!'.,GCQ%%
MT96Z'50J^UC?J='>7<%A93WER_EV]O&TLC8)VJHR3@<G@5@DY.R-FU%79XXG
MCOQMXXUV2V\(0I964+<R.B$JA(`:1FR`>"=JC.,_>QFO3^KT:,;U=7_6QY_M
MZM65J>B#6_$?Q&\":A8W.N7=OJ6GR-AA%&HC<\Y0L$5E;'([?7!%$*>'KIJ"
MLPG4KT6G-W1ZMH&OZ?XETB+4M-F\R%^"IX:-NZL.Q'^!&00:\^I3E3ERR.Z$
MXU(\T2'Q5XCMO"GA^XU6Y7S/+PL<0<*97/11G\SUP`3@XITJ3JS44*K45./,
MSRRRUWX@_$J2\_L:XBTC3(_EW*2@SNR%\P`N7QC.W`P.0,X/?*G0PUN?5_UT
M.%3K5[\NB/2?&.I:KHG@:_OK'9+J,$*G>D)*@Y`=PN3@`%FY)`QSD`UQ48QG
M547L=E64H4VUN<M\(_$.MZY_;$6L7_VOR/)DB.4.WS-[$97\/E/W<8P,8K?&
M4X0Y>16_X!CA:DYWYF>F5PG8>>?&/6I=+\%BUMYTCEOYA"PW$.8@"6VX/3A5
M/48;'>NW!04JEWT.3%SY:=EU.6^!.E[KW5M6=)1Y<:VT;8^1MQW,.G)&U._&
M[W%;X^>BB88*.KD>N:YI46N:%?:7-L"W4+1AF0.$8CAL=R#@CW%>=3FX24ET
M.^<>>+B?-OPYU672/'NDR1[RL\PMG17*AED^7GU`)#8]5'UKV\3!2I-'D8>7
M+41[E\4H99_AOK"0QO(P6-R%4DA5D4D_0`$GV%>5A6E6C<]+$J])V/G30]5E
MT/7;'5(=Y:UF60JKE"Z@\KGL",@^QKVJD%.+B^IY$)<DE)=#Z>\3ZY%I?@O4
M=8M[M%"VI>WG0!U+L,1D=006*^W/I7@TJ;E44&CVJD^6FY)GRC7T)X9]@ZE?
M1:7I=WJ$RNT5K"\SA`"Q502<9[\5\W&+E)174]^4N5-OH?-?A2#_`(2[XFVC
M7HB7[9>/=3)Y>Y&QND9-I/0X(YSU[U[E5^RHNW16_0\>DO:U5?JSZ>KP3V@H
M`^9_BO\`\E+U?_MC_P"B4KW<)_!7]=3QL5_%?]=#V7XK_P#)--7_`.V/_HY*
M\S"?QE_70]'%?PG_`%U.`^!/VW^VM6\O_CP^SKYW3_6;OW?OT\SIQZ]JZ\?R
M\J[_`-?\`Y,%?F?8T/CAXBEB2R\.PET651=7!Y`=<D(O!Y&0Q((ZA2*C`TT[
MU'Z%XRI:T$;/P5T9;'P?)J;*GFZC,2&5B3Y:$J`1T!W;SQV(_#/&SYJG+V-,
M'#EAS=SH/B-I46K>`M6CDV*UO";F-V0,5:/YN/0D`KGT8_2L<--PJHUQ$>:F
MSRSX(ZRMEXGN]*D**NH0Y3*DL9(\D`$<`;2YY]!^/?CH7@I=CBP<[3<>YK_'
MO_F7_P#MX_\`:=9X#[7R_4O&_9^9UGPBNX+CX=6,43[GMI)8I1@C:Q<OCW^5
MU/'K7/C$U6;9T85ITDD=S7(=(R*&*!"D,:1J69R%4`;B22?J223[FFVWN)*V
MP^D,\:^/?_,O_P#;Q_[3KT\!]KY?J>=C?L_,V?@=_P`B5>?]A!__`$7'66._
MB+T_S-<'_#?J>F5PG8?&\,TMO/'-!(\4L;!T=&(96'(((Z&OIFDU9GSR=M4?
M5_B__D2M>_[!\_\`Z+:OGJ/\2/JCW:O\.7HSY]U[1F'P[\*:XBN5*SVDI+#:
MI$TC)@=<G,G/3@=._L4Y_OIP]'^"/*G#]U&?R_$V=:\9RZM\+]`\.V6R6]F;
M[-<0P@EPL141KM());*'(/52!W`RA14*TJCV_P`]S2=;FHQ@M_\`(YSX@:7;
M:)XTO-,LTVV]M'!&O`!.(4RQP`,DY)/<DUOAYN=-2?G^9C7BH5'%?UH?1GB_
M_D2M>_[!\_\`Z+:O%H_Q(^J/7J_PY>C/FWP3/J]MXOL9="M8KK4EW^3%*<*W
M[MMV>5_AR>O:O;KJ#IM3=D>/1<E-<FYZY-X@^+,$$DS^%M-*QJ6(1M[$#T42
MDD^PYKSE3PK=N9_U\CO<\2OLK^OF=MX4U'4]5\-6E[K%G]COY-_FP>6T>W#L
M!\K<C(`//K7+5C&,VH.Z.FE*4H)R5F>`?%?_`)*7J_\`VQ_]$I7L83^"OZZG
ME8K^*_ZZ'0?%SQGJ=SJ=UX6:"*WM+>1'=HY&9IN-RYZ#&&4[<'#+U-8X.C%1
M53J:XJM)MT^AZEX(\&6W@O2)+2*?[3<32>9+<&,(6[*N.3@#L2>23WQ7GUZS
MK2NSNHT52C9'DWQQ_P"1UL_^P>G_`*,DKT<#_#?K_D<&,_B+T/3/A1_R332/
M^VW_`*.>N'%_QG_70[<+_"7]=3:\7_\`(E:]_P!@^?\`]%M65'^)'U1I5_AR
M]&>`?"C_`)*7I'_;;_T2]>QB_P""_P"NIY6%_BK^NA[?X\\'1>,M"%JLB0WL
M#>9;3,H(#8P5)QD*>,X[@'G&#Y6'K.C*_0]*O2]K&W4\&T'7=<^'/B>9'A>.
M1&$=W9R'"R*/Z\Y5AGKW!(/K5*<,1#\F>9"<Z$SZ/T#7]/\`$ND1:EILWF0O
MP5/#1MW5AV(_P(R"#7BU*<J<N61Z\)QJ1YHFG6984`>6_&_19[WP_8ZM$<II
M\C+*O'W9-HW9SV95&`#][VKOP,U&;B^IQ8R#<5)="E\"=4W66K:0[1#RY%N8
MUS\[;AM8XSR!M3MQN]Q5X^&JD1@I:.)Z?KFJQ:'H5]JDVPK:PM(%9P@=@.%S
MV).`/<UP4X.<E%=3MG+DBY'S5\/+#^TOB!HL'F^7LN!/G;G/E@R8_';CVS7N
M8B7+2DSQZ$>:JD>^?$B^ET[X>:S-"J%FA$)#`XVR,$/XX8X]Z\C#14JL4SU,
M1+EI-HX:WT9=9_9WA7:GFVBRW<;,Q`4I*Y;IU.S>`#QD_B.ISY,7ZZ?@<RAS
M87T.,^%&C+K'CVT,BHT5BINV5F()*X"XQW#LIP>,`_0]6+GR4GYZ'/A8<U1>
M0SXK_P#)2]7_`.V/_HE*>$_@K^NHL5_%?]=#Z(UVQEU3P]J>GP,BRW5K+"A<
MD*&92!G';FO%IR49J3Z'K3CS1:1\V_#>^BT[XAZ--,KE6F,("@9W2*4'X989
M]J]O$Q<J4DCR,/+EJIGU%7@GM!0!\S_%?_DI>K_]L?\`T2E>[A/X*_KJ>-BO
MXK_KH=S\;?#,!LK;Q';0;;A9!#=,D9.]2/E9CT&"-N<<[@,\`5R8&J[NF_D=
M.,IJW.C<^#WB!=6\'C3I'=KK3&\MMS%B8V)*')'`ZJ!DX"=LBLL93Y*G-T9K
MA*G-#E['(?':P\O6M)U'S<^?;M!Y>W[NQLYS[^9^GO71@)>ZXG/C8VDI'9_!
MN_\`MGP_B@\K9]BN)(,[L[\GS,^W^LQ^%<V-CRU;]SIPDKTK=C6^(VJQ:1X"
MU:2386GA-M&C.%+-)\O'J0"6QZ*?K6>&@Y54B\1+EIL\C^#.BSW_`(S_`+34
M[;?38V9SP=S.K(J]<C@L<X/W<=Z]'&S4:?+W.#"0;J<W8^A:\8]8\P^,OAJT
MN/##ZY!:V\=[;3(9I@-KR1G"8./O')3KT`./0]^"JM3Y&]#BQ=-.'.MRK\"?
MMO\`8FK>9_QX?:%\GI_K-O[SWZ>7UX].]5C^7F7?^O\`@DX*_*^QZS7G'>%`
M$-Y:07]E/9W*;[>XC:*1<D;E88(R.1P::;B[H32:LSPF#P]XL^&WC1[W2=(N
M-1L&9XT\I/-\Z#(.UBHRC?=YP.0<9&<^LZE+$4[2=G^IYBIU*%2\5=&GXR\0
M^+O&&GQ:)8>$-2LK:X9/.::!LNWRD+N*@(H;^(GD`$[>144:=*B^>4TRZU2K
M57(HM';?#WP-;>$=(2:6/=J]S&#<R-@F///EK@D8!ZD'DC/H!RXBNZLK+9'3
M0HJE&_4G^)EG<W_P]U2VL[:6XN'\K;%$A=FQ*A.`.3P":G"M1JIO^M!XA-TF
MD'PSL[FP^'NEVUY;2VUPGF[HI4*,N97(R#R."#1BFI56U_6@8=.-))F1\+_"
MTOAN?Q(76XCB>^-O`L\95FBCSMDSQN#;^H&/E_+7%5544?3\S/#4O9\WJ>>_
M$SPYKE_\0M4N;/1;^XMW\K;+%;.ZMB)`<$#!Y!%=F%J0C22;7],Y,13FZK:3
M/H6O&/6/&OB;\,KV[U.;7M!@\_S\O<VJ`!E8#ET'&[..1RVXYYSQZ>%Q45'D
MF>=B,.V^>!OV'Q'UPV4G]H^`]96[2,;/L]NY21\'.<J"@SC^]U]N<98:%_=F
MK&T<1.WO0=SH/`VH^(-5T2:]\1V?V.YDN#Y4'EF/;&%4?=/S#+!C\W//IBL:
M\:<96INYK1E.4;S5CR#XF>'-<O\`XA:I<V>BW]Q;OY6V6*V=U;$2`X(&#R"*
M]+"U(1I)-K^F>?B*<W5;29[KJ-A:>(="GLKF-S:WD."&CVNH(X.UA\K#@C(R
M"/:O)C)TY76Z/3E%3C9]3PWP#:^*/!WC!#=Z/J\>GNQAO%AM'E1@`0K<`@@-
M@Y7)QG&<X/JXATJU/1J_34\V@JE*>J=NI[+XM\+VGB[0GTR[=XB&$D,J]8Y`
M"`V.XY((]#V."/,HU72ES(]"K356/*SR3PQ+XV^'.IWNGCPW=:G9M("XACD9
M&(!PT;@$#.5SD$_*`<$<>E55'$14N:S."G[6@W'ENBSXQ7QE\1IT@L?#%[9:
M?9,2J7+>2TK'(#$.5!(`Z#.W)Y.:FC['#J[E=LJK[6OHHV2/5O"OARV\*>'[
M?2K9O,\O+22E`IE<]6./R'7``&3BO/JU'5GS,[J5-4X\J+FK:C_96F37OV.Z
MO/*Q^XM(_,E;)`X7C.,Y/L#40CS2M>Q4I<JO:YY!XLE\8?$>]@TJT\-W6FZ9
M#)YFZ\C,>XYVAV9@,85ON+D\M][C'I451PZYG*[\CSZOM:[Y5&R/4_"OARV\
M*>'[?2K9O,\O+22E`IE<]6./R'7``&3BN"K4=6?,SNI4U3CRHV:R-`H`*`"@
I`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
